Literature DB >> 2015876

Severe aplastic anemia (SAA): response to cyclosporin A (CyA) in vivo and in vitro.

J Tong1, A Bacigalupo, G Piaggio, O Figari, M T van Lint, D Occhini, T Lamparelli, F Gualandi, A M Marmont.   

Abstract

The aim of the present study was to test the effect of cyclosporin A (CyA) in vitro on CFU-GM growth from patients with severe aplastic anemia (SAA). For this purpose, bone marrow (BM) cells from 9 SAA patients and 5 healthy individuals were incubated with or without CyA and then cultured for CFU-GM growth in the presence of exogenous recombinant human GM-CSF (30 ng/ml). SAA patients were tested before or after treatment with CyA, or after treatment with antilymphocyte globulin (ALG). In 3 patients responding to CyA, the addition of CyA in vitro enhanced colony growth from 13 +/- 10 to 40 +/- 20/10(5) BM cells (p = 0.01) - the median increment of colony formation was 2.4-fold. In 5 ALG responders, CyA produced no increment of CFU-GM growth (from 14 +/- 26 to 15 +/- 16/10(5) BM cells, p = 0.1). CyA did not enhance significantly CFU-GM growth in normal controls (from 57 +/- 45 to 58 +/- 81/10(5) BM cells, p = 0.9). In conclusion, it would appear that some patients with SAA can respond to CyA in vivo and in vitro, and ALG responders are not necessarily among these. This is in keeping with different mechanisms of action of CyA and ALG and possibly with the existence of distinct pathogenetic pathways in SAA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015876     DOI: 10.1111/j.1600-0609.1991.tb00543.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

Review 1.  Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes.

Authors:  Neal S Young
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  Haematological improvement by long-term administration of recombinant human granulocyte-colony stimulating factor and recombinant human erythropoietin in a patient with severe aplastic anaemia.

Authors:  J Nawata; Y Toyoda; H Nisihira; K Honda; H Kigasawa; T Nagao
Journal:  Eur J Pediatr       Date:  1994-05       Impact factor: 3.183

4.  Immune suppression therapy in aplastic anemia: influencing factors on response and survival.

Authors:  J Y Jin; D W Kim; J W Lee; C W Han; W S Min; C W Park; C C Kim; D J Kim; H K Kim; H H Song
Journal:  Korean J Intern Med       Date:  1995-01       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.